Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670799 · ClinicalTrials.gov registry record · Early Phase 1
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT01670799: Completed Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by New Mexico Cancer Research Alliance.
NCT01670799 is a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 29 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01670799, a Early Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the anti-cancer effect of a pain medication called ketorolac (Toradol) on ovarian cancer cells in the abdominal (peritoneal) cavity after surgery for ovarian, fallopian tube or primary peritoneal cancer.
Primary Outcome
To determine the concentration of measurable levels of R and S- Ketorolac (and the percent racemic mixture) in the peritoneal cavity after intravenous (IV) administration in the post-operative patient after cytoreductive surgery.
Conditions Studied
Interventions
- DRUG Ketorolac
Study Locations (1)
New Mexico
- University of New Mexico Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-12 |
| Phase | Early Phase 1 |
What the finished NCT01670799 record still lists
NCT01670799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ketorolac is the first listed.
NCT01670799 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT01670799 about?
NCT01670799 is a clinical study titled "Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer". The purpose of this study is to evaluate the anti-cancer effect of a pain medication called ketorolac (Toradol) on ovarian cancer cells in the abdominal (peritoneal) cavity after surgery for ovarian, fallopian tube or primary peritoneal cancer.
What is the current status of trial NCT01670799?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2012-03. Estimated completion is 2015-12.
What conditions does trial NCT01670799 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT01670799?
The interventions under investigation include: Ketorolac (DRUG).
Who is sponsoring clinical trial NCT01670799?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01670799 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01670799's enrollment target sits among peer trials
29 262nd of 322 higher than 60 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Aspirin to Improve Immunological Features of Ovarian Tumors
RECRUITING · Early Phase 1
-
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
COMPLETED · Early Phase 1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia